 
Today, the U.S. Food and Drug Administration (FDA) announced the comment period for advancing health equity and facilitating access to digital health technologies for detecting prediabetes and type 2 diabetes, particularly in racial and ethnic minorities, has been extended until February 29, 2024.
Advancing health equity will ensure all patients, regardless of race, sexual orientation, gender identity, age, physical abilities, geographic location, educational background, and economic status will have access to safe, effective, and high-quality, medical technologies, including at home use devices, which may provide significant improvements in healthcare, quality of life, and wellness.
Please submit comments under docket number FDA-2023-N-4853 at www.regulations.gov by February 29, 2024.
Questions?
If you have questions, contact FDA Digital Health.
|
